Over the past twelve months, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)'s stock was 23.00%. During the same quarter in the prior year, the company earned $0.50 earnings per share. TheStreet raised Ligand Pharmaceuticals …
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) VP Charles S. Berkman sold 18,625 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $126.96, for a total transaction of …
Ligand Pharmaceuticals Inc (LGND): LGND stock is up 5.3% today ... Article printed from InvestorPlace Media, http://investorplace.com/2014/04/hottest-healthcare-stocks-now-lci-lgnd-agn-act-lci-lgnd-agn/.
Investors in Ligand Pharmaceuticals Inc (NASD: LGND) saw new options begin trading this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LGND options chain for the …
The institutional investor owned 21,445 shares of the biotechnology company's stock after buying an additional ... first …
LGND stock had a poor bottom line growth. The income statement is also called statement of revenue and expense.
Due to the fact that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has faced declining sentiment from the entirety of the hedge funds we track, it’s safe to say that there was a specific group of hedgies that decided to sell off their entire …
Ligand Pharmaceuticals Inc. (LGND) has $2.56 billion valuation. The stock increased 0.16% or $0.19 on August 4, reaching $122.06. About shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since …
It is being investigated as a treatment for acute myeloid leukemia by Amgen. Ligand Pharmaceuticals Incorporated …
Marlborough, MA, June 16, 2014 — Lemelson Capital Management, a private investment management firm, today announced that it is short Ligand Pharmaceuticals Inc. (NASDAQ:LGND), a biotechnology ... any intrinsic value of the …